论文部分内容阅读
AIM: To determine the baseline hepatitis B surface antigen(HBsAg) levels during the different phases of chronic hepatitis B(CHB) patients in China.METHODS: Six hundred and twenty-three hepatitis B virus or un-infected patients not receiving antiviral therapy were analyzed in a cross-sectional study. The CHB patients were classified into five phases: immunetolerant(IT, n = 108), immune-clearance(IC, n = 161), hepatitis B e antigen negative hepatitis(ENH, n = 149), low-replicative(LR, n = 135), and liver cirrhosis(LC, n = 70). HBsAg was quantified(Abbott ARCHITECT assay) and correlated with hepatitis B virus(HBV) DNA, and serum alanine aminotransferase/aspartate aminotransferase(ALT/AST) in each phase of CHB was also determined.RESULTS: Median HBsAg titers were different in each phase of CHB(P < 0.001): IT(4.85 log10 IU/mL), IC(4.36 log10 IU/mL), ENH(2.95 log10 IU/mL), LR(3.18 log10 IU/mL) and LC(2.69 log10 IU/mL). HBsAg titers were highest in the IT phase and lowest in the LC phase. Serum HBsAg titers showed a strong correlation with HBV viral load in the IC phase(r = 0.683, P < 0.001). No correlation between serum HBsAg level and ALT/AST was observed.CONCLUSION: The mean baseline HBsAg levels differ significantly during the five phases of CHB, providing evidence on the natural history of HBV infection. HBsAg quantification may predict the effects of immunemodulator or oral nucleos(t)ide analogue therapy.
AIM: To determine the baseline hepatitis B surface antigen (HBsAg) levels during the different phases of chronic hepatitis B (CHB) patients in China. METHODS: Six hundred and twenty-three hepatitis B virus or un-infected patients not receiving antiviral therapy were The CHB patients were classified into five phases: immunetolerant (IT, n = 108), immune-clearance (IC, n = 161), hepatitis B e antigen negative hepatitis , HBsAg was quantified (Abbott ARCHITECT assay) and correlated with hepatitis B virus (HBV) DNA, and serum alanine aminotransferase / aspartate aminotransferase ( ALT / AST) in each phase of CHB was also determined. RESULTS: Median HBsAg titers were different in each phase of CHB (P <0.001): IT (4.85 log10 IU / mL), IC (4.36 log10 IU / mL) (2.95 log10 IU / mL), LR (3.18 log10 IU / mL) and LC (2.69 log10 IU / mL). HBsAg titers were highest in the IT phase and lowest in the LC phase. Ser um HBsAg titers showed a strong correlation with HBV viral load in the IC phase (r = 0.683, P <0.001). No correlation between serum HBsAg level and ALT / AST was observed. CONCLUSION: The mean baseline HBsAg levels differ significantly during the five phases of CHB, providing evidence on the natural history of HBV infection. HBsAg quantification may predict the effects of immunemodulator or oral nucleos (t) ide analogue therapy.